Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
Clinical trial NCT05104333 · UNKNOWN
Trial details
- NCT number
- NCT05104333
- Sponsor
- China National Biotec Group Company Limited
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-01
- Primary completion
- 2022-11-01
- Enrollment
- 1440
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.